Healthcare company Fresenius Medical Care North America has invested in BioIntelliSense, which is working on a medical grade data services platform for continuous, remote patient monitoring.
The data services platform also uses algorithms and predictive analytics to deliver actionable clinical insights.
Fresenius Medical Care made the investment, which is part of BioIntelliSense’s series A financing, via its Ventures division. The company expects the BioIntelliSense platform to support its products and services to treat chronic kidney disease.
Fresenius Medical Care North America CEO Bill Valle said: “We are committed to helping more people living with chronic kidney disease through earlier interventions and are proud to invest in a company that is leading innovation in remote health sensors and services that we believe will help us accelerate change, further improve quality care and slow progression of chronic kidney disease.”
Valle added that the deal will allow the company’s medical staff to continuously monitor patients, in turn enabling timely interventions.
Fresenius Medical Care plans to leverage its advanced analytics and artificial intelligence expertise for the development of this platform.
The company will collaborate with BioIntelliSense to develop clinical pathways for notifying clinicians on the need for early intervention in a bid to avoid hospitalisation and reduce costs.
Fresenius Medical Care global chief medical officer Dr Frank Maddux said: “We believe this exciting new sensor technology and remote monitoring data service will improve patient health by delivering previously unavailable insights during that time between a treatment or a visit with their doctor.”
This February, Fresenius Medical Care acquired medical devices maker NxStage Medical for $2bn.